SCHEMBL7209622

SCHEMBL7209622

COc1ccccc1CC(=O)c1ccc(O)cc1.COc1ccccc1CC(=O)c1ccc(OCCN2CCCCC2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.58
ESR1 P03372 10/20 0.57
ESR2 Q92731 3/20 0.55
PSMB1 P20618 2/20 0.54
PSMB5 P28074 2/20 0.54
PSMB2 P49721 1/20 0.54
LTA4H P09960 1/20 0.54
KDM4E B2RXH2 1/20 0.53
ESRRG P62508 4/20 0.52
HRH3 Q9Y5N1 2/20 0.52
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.51
CYP1A2 P05177 1/20 0.51
CHRM2 P08172 1/20 0.51
CHRM4 P08173 1/20 0.51
CHRM5 P08912 1/20 0.51
CYP2D6 P10635 1/20 0.51
THRB P10828 1/20 0.51
CYP2C9 P11712 1/20 0.51
ADRA2C P18825 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5728349 0.96 L3MBTL1 (0.60) L3MBTL1ESR1ESR2PSMB1PSMB5
SCHEMBL7205222 0.81 LTA4H (0.62) ESR1ESR2PSMB1PSMB5PSMB2
SCHEMBL5725907 0.81 PSMB1 (0.61) ESR1ESR2PSMB1PSMB5PSMB2
SCHEMBL5725941 0.80 L3MBTL1 (0.68) L3MBTL1KDM4EALDH1A1LMNA
SCHEMBL10688643 0.78 LTA4H (0.66) PSMB1PSMB5PSMB2LTA4HKDM4E
SCHEMBL10685703 0.78 LTA4H (0.70) PSMB1PSMB5PSMB2LTA4HKDM4E
SCHEMBL7599803 0.77 ESR1 (0.58) ESR1ESR2PSMB1PSMB5PSMB2
SCHEMBL7599800 0.77 ESR1 (0.58) ESR1ESR2PSMB1PSMB5PSMB2
SCHEMBL7036874 0.77 LTA4H (0.67) PSMB1PSMB5PSMB2LTA4HKDM4E
SCHEMBL10676277 0.77 LTA4H (0.71) ESR1PSMB1PSMB5PSMB2LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030225130-A1 Triphenylalkene derivatives and their use as selective estrogen receptor modulators HORMOS MEDICAL OY LTD. 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225130-A1 Triphenylalkene derivatives and their use as selective estrogen receptor modulators ESR2, ESR1, GPER1 L3MBTL1 2169/4885ESR1 2/4885ESR2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.